Helping The others Realize The Advantages Of Tyrosinase-IN-12
MI-CP151 was a stage 1b randomised, double-blind, placebo managed, dose-escalation, multicentre study To guage numerous intravenous doses of sifalimumab, in Grownup patients with dermatomyositis or polymyositis (NCT00533091). Key trial goals were being to evaluate the security and tolerability of sifalimumab in dermatomyositis or polymyositis indiv